Amgen will buy Celgene's blockbuster psoriasis treatment Otezla for $13.4 billion in cash, according to The Wall Street Journal.
The sale is a win for Bristol-Myers Squibb, which is working to overcome antitrust concerns to secure approval for its $74 billion acquisition of Celgene.
Bristol-Myers said in June it would sell Otezla to ease concerns raised by the Federal Trade Commission because of a competing treatment it is developing.
Otezla had $1.61 billion in sales last year. Amgen expects sales from the drug to increase over the next five years.